加载中
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
收盘时
US$4.27
−US$0.06 · -1.39%
盘后
US$4.27
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日内区间
当前US$4.27
52周区间
当前US$4.27
盘中时间采用ET。市场数据可能有所延迟。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日内区间
当前US$4.27
52周区间
当前US$4.27
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 200万 USD | — | 134万 USD | 270.3万 USD | 270.3万 USD |
| 销货成本 | 198.7万 USD | — | — | — | — |
| 毛利 | 1.3万 USD | — | 134万 USD | 270.3万 USD | 270.3万 USD |
| 研究与开发 | 638.1万 USD | 632.4万 USD | 897.1万 USD | 2763.9万 USD | 2098.9万 USD |
| 销售、一般及管理费用 | 872万 USD | 645.7万 USD | 813.8万 USD | 1566.2万 USD | 593.7万 USD |
| 营业费用 | 1510.1万 USD | 1278.1万 USD | 1710.9万 USD | 4330.1万 USD | 2692.6万 USD |
| 利息收入 | 237.3万 USD | 498.3万 USD | 802.6万 USD | 357.3万 USD | 34.7万 USD |
| 利息支出 | — | 85.3万 USD | 358万 USD | — | — |
| 折旧和摊销 | 12.1万 USD | 19.3万 USD | 19.6万 USD | 5.8万 USD | 7.7万 USD |
| 营业利润 | −1508.8万 USD | −1278.1万 USD | −1576.9万 USD | −4059.8万 USD | −2422.3万 USD |
| 净利润 | 6405万 USD | −1906万 USD | 552.5万 USD | −3776.4万 USD | −2223.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年1月16日 | US$0.25Special | 2026年1月16日 | 2026年1月26日 |
除息 2026年1月16日
US$0.25
Special
2026年1月16日登记 · 支付日 2026年1月26日
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM368.81万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Russell 2000 ETFVTWO98.62万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC47.19万0.04%13.17亿 USD0.60%US$181.66-0.73%
Dimensional - US Small Cap ETFDFAS26.46万0.00%338.69亿 USD0.31%US$78.17-0.23%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC26.07万0.02%10.49亿 USD0.20%US$86.26-0.03%
Dimensional - US Core Equity 2 ETFDFAC25.93万0.00%885.96亿 USD0.21%US$45.31-0.04%
Avantis U.S. Small Cap Equity ETFAVSC24.08万0.01%30.82亿 USD0.25%US$69.97-0.01%
Vanguard Russell 2000 Value ETFVTWV15.85万0.01%14亿 USD0.06%US$185.97+0.08%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
